Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality.

Eur Heart J

Providence Heart and Lung Institute and The UBC James Hogg Research Center, St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6.

Published: August 2011

Aims: Surfactant protein-D (SP-D) is a lung-specific protein that is detectable in human plasma. We determined the relationship of circulating SP-D to cardiovascular disease (CVD) and total mortality in subjects with and without CVD.

Methods And Results: Plasma SP-D levels were measured in 806 patients who underwent coronary angiography to assess its predictive value for cardiovascular mortality. Serum SP-D levels were also measured in a replication cohort to assess its relationship with CVD events in 4468 ex- and current smokers without a known history of coronary artery disease (CAD). Patients who died during follow-up had significantly higher plasma SP-D levels than those who survived (median 85.4 vs. 64.8 ng/mL; P < 0.0001). Those in the highest quintile of SP-D had 4.4-fold higher risk of CVD mortality than those in the lowest quintile (P < 0.0001) independent of age, sex, and plasma lipid levels. In a group of current and ex-smokers without a known history of CAD, serum SP-D levels were elevated in those who died or were hospitalized for CVD compared with those who did not (median 99.8 vs. 90.6 ng/mL; P = 0.0001).

Conclusion: Circulating SP-D is a good predictor of cardiovascular morbidity and mortality and adds prognostic information to well-established risk factors such as age, sex, and plasma lipids and is a promising biomarker to link lung inflammation/injury to CVD.

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehr124DOI Listing

Publication Analysis

Top Keywords

sp-d levels
16
surfactant protein-d
8
cardiovascular morbidity
8
morbidity mortality
8
sp-d
8
circulating sp-d
8
plasma sp-d
8
levels measured
8
serum sp-d
8
age sex
8

Similar Publications

Article Synopsis
  • The study aimed to identify serum surfactant protein D (SP-D) levels that can aid in the diagnosis and prognosis of COVID-19, while also developing a new prognostic scale called the CHARISMA Score.
  • Researchers conducted assessments on 64 COVID-19 patients and 16 healthy individuals, comparing various subgroups based on factors such as PCR results and severity of illness, ultimately finding significant differences in serum SP-D levels.
  • Results indicated that higher SP-D levels and CHARISMA scores correlated with greater disease severity and mortality risk, establishing the potential of these measures for predicting patient outcomes in COVID-19 pneumonia.
View Article and Find Full Text PDF

Rhodococcus equi (R. equi) is a primary cause of pyogranulomatous pneumonia of foals between three weeks and five months of age. Early diagnosis of rhodococcal pneumonia has always been considered a preferable approach as it can lead to more successful treatment and better outcomes.

View Article and Find Full Text PDF

Background: This study investigated poor prognostic factors for the relapse of interstitial lung disease (ILD) in patients with microscopic polyangiitis (MPA) after remission induction therapy.

Methods: We enrolled patients diagnosed with MPA complicated by ILD according to the Chapel Hill Consensus definition from 2001 to 2023 in multiple institutions in the REVEAL cohort. All patients who were treated with immunosuppressive therapy were followed up, and those who relapsed with ILD were extracted in this study.

View Article and Find Full Text PDF

Background: Biomarkers that change in response to nintedanib in subjects with idiopathic pulmonary fibrosis (IPF) would be valuable. We investigated the effects of nintedanib on circulating biomarkers in subjects with IPF in the INMARK trial.

Methods: Subjects with IPF were randomised 1:2 to receive nintedanib 150 mg twice daily or placebo for 12 weeks, after which all patients received open-label nintedanib for 40 weeks.

View Article and Find Full Text PDF

Idiopathic pulmonary fibrosis (IPF) is a prevalent chronic lung condition of unknown etiology characterized by fibrosis and inflammation. Lung scarring progresses owing to cytokines and immune cells that promote inflammation and fibrosis in idiopathic pulmonary fibrosis (IPF). The anti-inflammatory and anti-fibrotic properties of the ethyl acetate extract of Clerodendrum phlomidis (CPEA), derived from the Indian plant "agnimantha," are recognized in traditional Ayurvedic medicine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!